» Articles » PMID: 38600340

ECLIM-SEHOP: How to Develop a Platform to Conduct Academic Trials for Childhood Cancer

Abstract

Introduction: ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation.

Methods: The platform's database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up/conduct metrics since its creation until November 2023 were extracted.

Results: ECLIM-SEHOP has supported 47 studies: 29 clinical trials and 18 observational studies/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies: 16 trials recruiting 584 patients and nine observational studies/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months.

Discussion: ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.

References
1.
Nordenmalm S, Tomasi P, Pallidis C . More medicines for children: impact of the EU paediatric regulation. Arch Dis Child. 2018; 103(6):557-564. DOI: 10.1136/archdischild-2017-313309. View

2.
Hardin E, Schmid S, Sommerkamp A, Bodden C, Heipertz A, Sievers P . LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro Oncol. 2023; 25(11):2087-2097. PMC: 10628936. DOI: 10.1093/neuonc/noad078. View

3.
Rubio-San-Simon A, Hladun Alvaro R, Juan Ribelles A, Castaneda Heredia A, Guerra-Garcia P, Verdu-Amoros J . The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clin Transl Oncol. 2021; 23(12):2489-2496. DOI: 10.1007/s12094-021-02649-y. View

4.
Botta L, Gatta G, Capocaccia R, Stiller C, Canete A, Dal Maso L . Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study. Lancet Oncol. 2022; 23(12):1525-1536. DOI: 10.1016/S1470-2045(22)00637-4. View

5.
Gatta G, van der Zwan J, Casali P, Siesling S, Dei Tos A, Kunkler I . Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011; 47(17):2493-511. DOI: 10.1016/j.ejca.2011.08.008. View